Literature DB >> 1463953

London after Tomlinson. Care in the capital: what needs to be done.

D Metcalfe1.   

Abstract

One of the aims of the Tomlinson report is to shift more care from the secondary to the primary sector in London. But the primary sector is already underresourced and overloaded. The capital has a heterogeneous population which often makes inappropriate demands on general practitioners. Many premises are inadequate and there are insufficient support staff. David Metcalfe emphasises that London is special and that the shift will not become a reality unless these problems are tackled. He suggests the establishment of different models of practice centres which could treat some of the patients who now go to accident and emergency departments. Some would be the night emergency service base, some would have primary care beds, and each would have a different mix of specialist support.

Entities:  

Mesh:

Year:  1992        PMID: 1463953      PMCID: PMC1883650          DOI: 10.1136/bmj.305.6862.1141

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  3 in total

1.  The "five minute" consultation: effect of time constraint on clinical content and patient satisfaction.

Authors:  D C Morrell; M E Evans; R W Morris; M O Roland
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-29

2.  Does the underprivileged area index work?

Authors:  R Leavey; J Wood
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-14

3.  Identification of underprivileged areas.

Authors:  B Jarman
Journal:  Br Med J (Clin Res Ed)       Date:  1983-05-28
  3 in total
  3 in total

1.  Improving London's health service.

Authors:  J Smith
Journal:  BMJ       Date:  1993-02-27

2.  Primary care development zones.

Authors:  V Beardshaw; P Gordon; D Plamping
Journal:  BMJ       Date:  1993-01-30

3.  Predicting the workload in urban general practice in The Netherlands from Jarman's indicators of deprivation at patient level.

Authors:  S A Reijneveld
Journal:  J Epidemiol Community Health       Date:  1996-10       Impact factor: 3.710

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.